Journal of Pathology and Translational Medicine

Original Articles

Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer: Soyoung Im, Changyoung Yoo, Ji-Han Jung, Ye-Won Jeon, Young Jin Suh, Youn Soo Lee, Hyun Joo Choi; Korean J Pathol. 2013;47(6):534-540. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.534

7,129 View
61 Download
9 Crossref

Background

The microtubule-associated protein Tau binds to both inner and outer surfaces of microtubules, leading to tubulin assembly and microtubule stabilization. The aim of this study was to evaluate the significance of Tau, α-tubulin, and βIII-tubulin expression in breast carcinoma and to assess their relationships with disease progression in the context of taxane treatment.

Methods

Immunohistochemical expressions of Tau, α-tubulin, and βIII-tubulin were assessed in 183 breast cancer cases. Expression was correlated with clinicopathologic parameters, disease progression and overall survival.

Results

Tau expression was correlated with lymph node metastasis and estrogen receptor (ER) positivity (p=.003 and p<.001, respectively). Loss of α-tubulin was significantly correlated with distant metastasis (p=.034). Loss of βIII-tubulin was correlated with lymph node metastasis and ER positivity (p=.004 and p<.001, respectively). In taxane-treated cases, Tau expression and loss of α-tubulin and βIII-tubulin expression were related to disease progression (p=.001, p=.028, and p=.030, respectively). Tau expression was associated with a worse survival rate in taxane-treated patients (p=.049).

Conclusions

Tau expression and loss of α-tubulin and βIII-tubulin expression were correlated with aggressive behavior in taxane-treated breast cancer. Further evaluation of Tau, α-tubulin and βIII-tubulin may be useful in predicting clinical behavior and seeking therapeutic measures in taxane-based chemotherapy for breast cancer.

Citations

Citations to this article as recorded by

Tubulin Isotypes: Emerging Roles in Defining Cancer Stem Cell Niche
Tessy Thomas Maliekal, Dhrishya Dharmapal, Suparna Sengupta
Frontiers in Immunology.2022;[Epub] CrossRef
RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage
Brittany M. Haynes, Kristen Cunningham, Malathy P. V. Shekhar
BMC Cancer.2022;[Epub] CrossRef
Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat
Alena Pastornická, Silvia Rybárová, Slávka Drahošová, Jozef Mihalik, Andrea Kreheľová, Andriana Pavliuk-Karachevtseva, Ingrid Hodorová
International Journal of Molecular Sciences.2021; 22(12): 6363. CrossRef
Intelligently thermoresponsive flower-like hollow nano-ruthenium system for sustained release of nerve growth factor to inhibit hyperphosphorylation of tau and neuronal damage for the treatment of Alzheimer's disease
Hui Zhou, Youcong Gong, Yanan Liu, Anlian Huang, Xufeng Zhu, Jiawei Liu, Guanglong Yuan, Li Zhang, Ji-an Wei, Jie Liu
Biomaterials.2020; 237: 119822. CrossRef
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
J. R. Ribeiro, C. Schorl, N. Yano, N. Romano, K. K. Kim, R. K. Singh, R. G. Moore
Journal of Ovarian Research.2016;[Epub] CrossRef
A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases
Tatiana M. Tilli, Cláudio da Silva Castro, Jack A. Tuszynski, Nicolas Carels
BMC Genomics.2016;[Epub] CrossRef
Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection
Chao Lin, Guo-chao Zhao, Ya-dong Xu, Dan-song Wang, Da-yong Jin, Yuan Ji, Wen-hui Lou, Wen-chuan Wu
Oncotarget.2016; 7(37): 60657. CrossRef
Oblongifolin C inhibits metastasis by up-regulating keratin 18 and tubulins
Xiaoyu Wang, Yuanzhi Lao, Naihan Xu, Zhichao Xi, Man Wu, Hua Wang, Xiyi Li, Hongsheng Tan, Menghong Sun, Hongxi Xu
Scientific Reports.2015;[Epub] CrossRef
Regulation of human MAPT gene expression
Marie-Laure Caillet-Boudin, Luc Buée, Nicolas Sergeant, Bruno Lefebvre
Molecular Neurodegeneration.2015;[Epub] CrossRef

Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer.: Jinyoung Yoo, Byoung Yong Shim, Chang Young Yoo, Seok Jin Kang, Kyo Young Lee; Korean J Pathol. 2009;43(5):435-440.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.5.435

3,418 View
37 Download
1 Crossref

Abstract PDF

BACKGROUND
Taxane-platinum combinations are often used as first-line treatments for patients with advanced non-small cell lung cancer (NSCLC). Response to chemotherapy for these patients is still poor. The aim of our study was to investigate, for this disease, whether KRAS and Tau proteins affect responses to taxane-platinum combinations.
METHODS
Expression of KRAS and Tau was examined immunohistochemically in 71 tumor samples obtained from patients with stage IIIB or IV NSCLC prior to combination therapy. Expression was correlated with tumor responses.
RESULTS
The response rate was 55% (39 of 71). KRAS and Tau were expressed in seven (10%) and 31 (44%) patients, respectively. All seven KRAS-positive patients were non-responders (p=0.014). Among Tau-positive patients, 35% (11 of 31) responded to therapy, whereas a partial response was observed in 70% (28 of 40) of Tau-negatives (p=0.045). Two were positive for both, and they were non-responders. In patients negative for both, the response rate was 71% (25 of 35) (p=0.012).
CONCLUSIONS
Expression of KRAS and Tau are significantly correlated with poor responses to this combination therapy in advanced NSCLC patients, and may be a useful marker for chemoresistance.

Citations

Citations to this article as recorded by

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer
Stéphanie Papin, Paolo Paganetti
Brain Sciences.2020; 10(11): 862. CrossRef

First
Prev
Page of 1
Next
Last

Search